Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

HEC, Lannet Eye US Generic Insulin Market Through Extended Alliance

This article was originally published in PharmAsia News

Executive Summary

Following bilateral distribution and contract manufacturing agreements signed in 2014, China’s HEC Pharm and Lannett have extended their partnership for generic insulin glargine development to the US market. Clinical trial applications have been filed in China and HEC expects generic insulins to give more impetus to its business growth after 2018.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel